Form 4: Prothena Director Dennis Selkoe Receives Stock Options

Director Dennis J. Selkoe was granted 27,000 stock options in Prothena Corporation as part of standard director compensation.

Summary

• Director Dennis J. Selkoe received a grant of 27,000 stock options on May 15, 2026.
• The options have an exercise price of $9.76 per share.
• The options are set to expire on May 15, 2036.
• Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the director maintaining continuous service with the company.

Future Outlook

The options vest in full on the earlier of May 15, 2027, or the date of the 2027 annual general meeting, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of options on the earlier of May 15, 2027, or the 2027 annual general meeting.

Key Dates

Keywords

Prothena, PRTA, Director Compensation, Stock Options, Insider Transaction, Biotech